DXCM vs. TNDM

In the year-to-date period, DXCM achieves a 15.31% return, which is significantly higher than TNDM's -11.94% return. Over the past 10 years, DXCM has outperformed TNDM with an annualized return of 18.78%, while TNDM has yielded a comparatively lower -13.54% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for DexCom, Inc. (DXCM) and Tandem Diabetes Care, Inc. (TNDM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current DXCM Sharpe Ratio is -0.43, which is lower than the TNDM Sharpe Ratio of 0.46. The chart below compares the historical Sharpe Ratios of DXCM and TNDM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither DXCM nor TNDM has paid dividends to shareholders.

The maximum DXCM drawdown since its inception was -94.61%, roughly equal to the maximum TNDM drawdown of -99.25%. Use the drawdown chart below to compare losses from any high point for DXCM and TNDM. For additional features, visit the drawdowns tool.

DexCom, Inc. (DXCM) and Tandem Diabetes Care, Inc. (TNDM) have volatilities of 8.54% and 8.97%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between DexCom, Inc. and Tandem Diabetes Care, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.